Anixa Biosciences Releases Data Presented at AACR Artificial Intelligence Conference

News provided by

Oct 17, 2018, 07:00 ET

SAN JOSE, Calif., Oct. 17, 2018 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, presented the results from its ongoing study utilizing Cchek™, its artificial intelligence (AI) driven early cancer detection technology, at the 30th Anniversary AACR Special Conference – Convergence: Artificial Intelligence, Big Data and Prediction in Cancer. This AACR special conference covered the state of research in understanding cancer from incident to early diagnosis, prevention, and treatment using big data and machine learning. The meeting was held October 14–17, 2018 in Newport, Rhode Island and was attended by global leaders in the intersection of cancer research and artificial intelligence.

Anixa, for the first time, presented data demonstrating the ability of Cchek™ to distinguish, among patients scheduled for biopsy, those who have high risk prostate cancer and those who have benign conditions or low grade cancer, for whom surgery is not required and a biopsy is unnecessary. In addition, Anixa's Cchek™ data showed the ability to distinguish healthy males from high risk prostate cancer patients with a sensitivity of 89% and a specificity of 100%. This study further demonstrated the potential for Cchek™ to reduce the number of unnecessary prostate biopsies by up to 56%, while still retaining 89% sensitivity for detecting prostate cancers.

Dr. Amit Kumar, Anixa President and CEO stated, "We are pleased with the results of our ongoing study presented at the AACR AI conference, and we are excited about the potential for us to dramatically reduce the number of unnecessary prostate biopsies. The ability to distinguish between high risk prostate cancer patients and those with a benign condition or low grade, non-surgically treated cancer is significant, and is a distinct differentiator between Cchek™ and many other liquid biopsy tests being developed today."

The poster presentation has been placed on the Company's website and can be viewed at https://www.anixa.com/cchek/recent-data.

About Anixa Biosciences, Inc.
Anixa, a cancer-focused biotechnology company, is harnessing the body's immune system in the fight against cancer. Anixa is developing both diagnostics and therapeutics to detect cancer early, when it is most curable, and to treat those afflicted once diagnosed. It is developing the Cchek^TM platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy. It is also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer. Anixa also continually examines emerging technologies in complementary or related fields for further development and commercialization. Additional information is available at www.anixa.com.

Forward-Looking Statements: Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

SOURCE Anixa Biosciences, Inc.